Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Evaluation of Functional Cardiac Measures and Response to Treatment Initiation in Patients with Systemic Light-Chain (AL) Amyloidosis: Results from a Single Site Retrospective Study

Jeffrey Thompson, Julia Catini, David Ouyang, I-Min Chiu, Candida Cristina Quarta

Blood (2024) 144 (Supplement 1): 4677.

https://doi.org/10.1182/blood-2024-205783

Published: 2024

Journal Articles

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, Richa Manwani, Chandrasekhar Udata, Juliana Ianus, John Tripptree, Julia Catini, Candida Cristina Quarta

Blood (2023) 142 (Supplement 1): 540.

https://doi.org/10.1182/blood-2023-186515

Published: 2023

Journal Articles

1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia

Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, Mark Tulchinskiy, Chandrasekhar Udata, Girly Ramirez, Kate Szymaniak, Julia Catini, Candida Cristina Quarta

Blood (2022) 140 (Supplement 1): 10127–10128.

https://doi.org/10.1182/blood-2022-162597

Published: 2022

Journal Articles

C11-1F4 Binds and Promotes Clearance of Light Chain Fibrils By Phagocytosis

Sahar Esteghamat, Dhirender Ahlawat, Steve Raiker, Melissa Batonick, Candida Cristina Quarta, Sahar Usmani-Brown

Blood (2022) 140 (Supplement 1): 12442–12443.

https://doi.org/10.1182/blood-2022-159766

Published: 2022

Journal Articles

Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database

Julia Catini, Quan Doan, Jennifer Evans, Andrew Rava, Thomas Defay, Guillermo Del Angel, Megan Teynor, Candida Cristina Quarta, Mathew S. Maurer, Isabelle Lousada

Blood (2022) 140 (Supplement 1): 4330–4331.

https://doi.org/10.1182/blood-2022-162694

Published: 2022

Journal Articles

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

Ashutosh D. Wechalekar, John Silowsky, Eileen Daniel, Mark Harnett, Michael Spector, Susan B. Sobolov, Candida Cristina Quarta, Michael R. Kurman, Mark Tulchinskiy, Amit Bhattacharyya, Michaela Liedtke

Blood (2021) 138 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2021-152488

Published: 2021

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Faye Sharpley, Tamer Rezk, Thirusha Lane, Cristina Quarta, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (7): 761–764.

https://doi.org/10.1182/blood-2018-04-846493

Published: 2018

Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 5357.

https://doi.org/10.1182/blood.V126.23.5357.5357

Published: 2015

NARROW

Evaluation of Functional Cardiac Measures and Response to Treatment Initiation in Patients with Systemic Light-Chain (AL) Amyloidosis: Results from a Single Site Retrospective Study

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia

C11-1F4 Binds and Promotes Clearance of Light Chain Fibrils By Phagocytosis

Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only